Substance Name: MEDI 551 US National Library of Medicine, National Institutes of Health Accessed on 25 Jun 2014 from http://chem.sis.nlm.nih.gov/chemidplus/rn/1299440-37-1.
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, et al. J Pharmacol Exp Ther. 2010 Oct; 335(1):213-22. Epub 2010 Jul 06. PMID: 20605905. Abstract
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall'Acqua W, Tedder T, Kiener P, Coyle AJ, Wu H, et al. Br J Haematol. 2011 Nov; 155(4):426-37. Epub 2011 Sep 09. PMID: 21902688. Abstract
Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies. Matlawska-Wasowska K, Ward E, Stevens S, Wang Y, Herbst R, Winter SS, Wilson BS Leukemia. 2013 Jun; 27(6):1263-74. Epub 2013 Jan 11. PMID: 23307031. Abstract
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis ClinicalTrials.gov, 3 Dec 2013 Accessed on 25 Jun 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01585766.
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) ClinicalTrials.gov, 29 Jan 2014 Accessed on 25 Jun 2014 from http://clinicaltrials.gov/ct2/show/NCT01466153.
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma ClinicalTrials.gov, 10 Oct 2013 Accessed on 25 Jun 2014 from http://clinicaltrials.gov/ct2/show/NCT00946699.
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma ClinicalTrials.gov, 23 Jun 2014 Accessed on 25 Jun 2014 from http://clinicaltrials.gov/ct2/show/NCT01861340.
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) ClinicalTrials.gov, 8 Oct 2013 Accessed on 25 Jun 2014 from http://clinicaltrials.gov/ct2/show/NCT01453205.
A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies ClinicalTrials.gov, 14 May 2014 Accessed on 25 Jun 2014 from http://clinicaltrials.gov/ct2/show/NCT00983619.
A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders ClinicalTrials.gov, 1 Oct 2015 Accessed on 17 Dec 2015 from https://www.clinicaltrials.gov/ct2/show/NCT02200770.
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Cree BAC, Bennett JL, Sheehan M, Cohen J, Hartung H-P, Aktas O, Kim H J, Paul F, Pittock S, Weinshenker B, et al. Mult Scler. 2015 Dec 14. PMID: 26666258. Abstract